Hey everyone, which stocks are currently on your watchlist? I'll make a start:

$ADP (+0,04 %)

$ALV (-2,72 %)

$BELA (-2,95 %)

$AJG (-3,15 %)

$CAMX (+1,33 %)

$7013 (-0,49 %)

$BLK (-0,79 %)

Dear Community,

How often have I been annoyed that I was thrown out of the race with an SL, but this morning I was really happy when $CAMX (+1,33 %) plummeted by a whopping 25% for no apparent reason. The SL that I happened to place last night took hold at € 60.20 and saved me from falling to just over € 49.

And what does a (brave) hare do in such a case? He takes the small profit, adds a lot and buys 30 more shares directly at € 49.44. 😂

Perhaps the new entry point has now been reached for some interested parties.

Best regards 🐰

André

Just tell us the title and preferably why you find it so interesting.

For your information $CAMX (+1,33 %) I already own

Many thanks in advance for all answers

$CAMX (+1,33 %)

Hello my dears,

DER AKTIONÄR has now also discovered my portfolio stock Camurus. That's why I'm staying invested.

Perhaps the editors will also read my posts.

The article from DER AKTIONÄR highlights the Swedish biotech company Camurus as a current "top pick" and highlights its strategic partnership with the US pharmaceutical giant Eli Lilly.

🔍 Key messages of the article

• Volatile share price performanceCamurus shares have fluctuated considerably in recent months, but are currently moving significantly upwards again (+4.22%).
• Analyst optimism: The experts at ABG Sundal Collier see considerable potential and are confident that the share will reach new highs.
• Strategic partnership: The cooperation with Eli Lilly is seen as a door opener for new market opportunities and dimensions.
• Key market figures:
• Share price: € 65.50
• Market capitalization: € 3.79 billion
• P/E RATIO: 51
• Performance: +23.23 % year-on-year
• RecommendationDER AKTIONÄR sees good reasons for an investment and points to the long-term growth story.

AKTIONÄR-Tipp Camurus: "Top-Pick" – mit Eli Lilly in neue Dimensionen - DER AKTIONÄR

$CAMX (+1,33 %)

Hello folks,

I've already introduced you to Camurus several times, so I won't write too much more about it today.

Why am I introducing the company to you again anyway?

Because the share fits well into my new category

"Points kings" category.

This can be seen in the Traderfox quality and growth check below.

Which most of my readers will already be familiar with.

Why am I reminding you of this share again today?

When I bought the share 5 months ago (see red arrow), I assumed that it would break out of the longer sideways movement. I like the fundamentals of the company (see post below from 5 months ago).

But the time for the biotech sector had not yet come. As a result, I first went into negative territory with the share and thus had a good opportunity to buy more.

However, we have seen a sector rotation over the last few days. With good momentum for biotech stocks. Which we can also observe with Camurus (yellow area).

Ladies and gentlemen, could the share be of interest to you now?

@Multibagger
@Dividendenopi
@TomTurboInvest
@All-in-or-nothing
@TradingHase
@Klein-Anleger and everyone else.

📈 1. trend analysis (short / medium / long)

(purely based on price, daily range, 52-week range and price level)

🔹 Short-term trend (days to a few weeks)

• Strong daily increase: +3,77 %
• Closing price near daily high: 61.95 vs. 62.25
• Intraday range shows clear buyer dominance.

→ Short-term trend: clearly upward (bullish).

🔹 Medium-term trend (weeks to months)

• Price is well above the middle of the 52-week range (41.10 - 67.90)
• Current share price: 61,95i.e. in the upper third.
• No indications of a trend break in the visible data range.

→ Medium-term trend: stable upward trend.

🔹 Long-term trend (months to 1 year)

• 52-week low: 41,10
• 52-week high: 67,90
• Current price close to high.

→ Long-term trend: clearly positive, structurally bullish.

🧱 2. supports & resistances

(derived from daily range, 52-week range and price levels)

🔮 3. scenario model (bullish / neutral / bearish)

(derived purely from chart data and trend situation)

🟢 Bullish scenario

Trigger: Break above EUR 62.25 Targets:

• EUR 65.00
• 67.90 EUR (52-week high)
• A new high would be possible above this (trend continuation)

Probability: High, as all trends are bullish.

⚪ Neutral scenario

Trigger: Setback to the EUR 58.95 - 56.00 zone Behavior:

• Sideways phase
• Consolidation after strong rise
• Buyers only appear again at EUR 56-59

Probability: Medium.

🔴 Bearish scenario

Trigger: Break below EUR 55 Consequences:

• Acceleration towards EUR 52-53
• Further pressure: Test of the 52-week low (EUR 41.10)

Probability: Low, as trend structure is clearly positive.

🎯 Conclusion

Camurus shows in the Onvista chart a clean bullish overall picture:

• Short-, medium- and long-term uptrend
• Buyer dominance in the course of the day
• Price in the upper part of the annual range
• Clear upward resistance, but no structural weaknesses visible

🔮 5. what does this mean for you as an investor?

🟢 Bullish

• The price is moving in the upper channel area in all time frames
• This speaks for trend strength and further potential

⚪ Neutral

• A setback to the zone 58-59 EUR would be completely normal
• This is where the lower short-term edge of the channel

🔴 Bearish

• Only below 55 EUR the long-term channel would be violated
• That would be a structural warning signal

Chart analysis created via Copilot, the rest was created without AI.

Camurus purchased: strong sales and profit growth, high margins, pipeline provides additional upside.

Many thanks to @Tenbagger2024 for your great ideas and inspiration.

$CAMX (+1,33 %)
$GUBRA (-0,09 %)

Ladies and gentlemen, I remain invested in Camurus.

The two Scandinavian biotech companies Camurus and Gubra are pooling their expertise. An exclusive cooperation and license agreement has been signed with the aim of developing a long-acting therapeutic option for the treatment of hypoparathyroidism, an underactive parathyroid gland.

This research and development program combines Gubra's parathyroid hormone (PTH) analog, developed using its proprietary peptide discovery platform "streaMLine", with Camurus' FluidCrystal technology to enable prolonged, patient-friendly dosing, according to a press release.

"Given the promising initial development data, we look forward to this collaboration combining Gubra's strengths in drug discovery and preclinical expertise with Camurus' technology, late-stage development capabilities and commercialization expertise," said Markus Johnsson, Senior Vice President R&D at Camurus.

Under the terms of the agreement, Camurus will develop and commercialize the product, while Gubra has the option to co-finance the development of the product. Gubra will in turn receive staggered license fees based on the level of financial participation.

CONCLUSION

Gubra has partnered another asset from its development pipeline at a relatively early stage. This clearly speaks for the Danes' strong expertise in drug discovery. With Camurus, the company has gained an excellent partner from Lund, Sweden, which also has a highly interesting technology platform to offer. Both stocks continue to be excellent long-term portfolio additions for speculative investors.

$CAMX (+1,33 %)
$NOVO B (+5,46 %)

Hello my dears,

For those who are already disappointed with the Danish 🇩🇰 Novo. I would like to remind you once again of the Swedish 🇸🇪 Camurus.

$CAMX (+1,33 %)

Here, too, I remain invested. @Multibagger

The obesity market continues to be one of the hottest areas in the biopharma sector - not least due to the bidding war between Pfizer and Novo Nordisk for Metsera. Recently, the focus of development has shifted to other parameters in addition to absolute weight reduction over a certain period of time. The Swedish company Camurus could contribute to this.

The company, which has its roots in the Swedish University of Lund, has its innovative FluidCrystal technology. The Scandinavians have designed the platform's approach for a long-lasting release of active ingredients. This enables effective treatment over longer periods of time with a single injection.

Camurus has now demonstrated this potential with the administration of semaglutide (Novo Nordisk's active ingredient contained in Ozempic and Wegovy). The substance CAM2056 was designed in such a way that in the long term only one monthly administration of semaglutide is necessary. Otherwise, the much-cited "weight loss injection" must be administered weekly.

The study showed that semaglutide administered as two biweekly starting doses, followed by two monthly doses, was well tolerated until the highest starting dose was reached. Particularly exciting: the results of the phase 1b study show a weight reduction of 9.3 percent with CAM2056 compared to 5.2 percent with weekly semaglutide administered on day 85.

"We are very pleased with the Phase 1b data, which show that CAM2056 is well tolerated and produces a dose-dependent reduction in body weight and A1c that matches or exceeds that observed with weekly semaglutide," summarized Camurus CEO Fredrik Tiberg. "The study data suggest that CAM2056 enables rapid dose titration without compromising tolerability, while allowing convenient monthly dosing. Further evaluation of CAM2056 is planned in an upcoming Phase 2b study."

Conclusion

Camurus once again demonstrates the platform potential of its FluidCrystal technology. The Swedes are already working with Eli Lilly in this area, while Novo Nordisk is relying on the expertise of Danish company Ascendis Pharma. Irrespective of this, Camurus can help to extend dosing intervals and reduce the inconvenience of injections. In the opinion of the AKTIONÄR, the potential of the Swedes in this area is clearly underestimated. Courageous investors should buy (stop: 47 euros).

https://www.deraktionaer.de/artikel/pharma-biotech/aktionaer-tipp-camurus-gamechanger-im-adipositas-markt-kurssprung-20390010.html